MAP2K7 and cancer: Current phase I/II clinical trials (NCT00281957, NCT01614301, and NCT01565837) investigating combination treatments which include Sorafenib, MEK inhibitors, chemotherapy agents, and stereotactic ablative radiation therapy along with Temsirolimus in patients with metastatic melanoma or advanced cancers are underway.